{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:01:31Z","timestamp":1758636091024},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T00:00:00Z","timestamp":1343433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T00:00:00Z","timestamp":1343433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10637-012-9847-1","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T02:50:41Z","timestamp":1343443841000},"page":"206-212","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel"],"prefix":"10.1007","volume":"31","author":[{"given":"Alexander N.","family":"Wein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Leppla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,28]]},"reference":[{"issue":"Suppl 7","key":"9847_CR1","doi-asserted-by":"publisher","first-page":"vii154","DOI":"10.1093\/annonc\/mdq373","volume":"21","author":"M Hallek","year":"2010","unstructured":"Hallek M, Pflug N (2010) Chronic lymphocytic leukemia. Ann Oncol 21(Suppl 7):vii154\u2013vii164","journal-title":"Ann Oncol"},{"issue":"2","key":"9847_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/00043426-199122000-00016","volume":"13","author":"L White","year":"1991","unstructured":"White L (1991) Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol 13(2):189\u2013201","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"1","key":"9847_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1349-7006.2009.01373.x","volume":"101","author":"K Kawai","year":"2010","unstructured":"Kawai K, Akaza H (2010) Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer. Cancer Sci 101(1):22\u201328","journal-title":"Cancer Sci"},{"issue":"10","key":"9847_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2010-0322","volume":"15","author":"F Grossi","year":"2010","unstructured":"Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY (2010) Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist 15(10):1102\u20131112","journal-title":"Oncologist"},{"issue":"3 Pt 2","key":"9847_CR5","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1006\/gyno.1994.1347","volume":"55","author":"T Thigpen","year":"1994","unstructured":"Thigpen T, Vance R, Puneky L, Khansur T (1994) Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55(3 Pt 2):S97\u2013S107","journal-title":"Gynecol Oncol"},{"issue":"1","key":"9847_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3816\/CBC.2000.n.002","volume":"1","author":"JA Sparano","year":"2000","unstructured":"Sparano JA (2000) Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 1(1):32\u201340","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"9847_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","volume":"7","author":"RD Baird","year":"2010","unstructured":"Baird RD, Tan DS, Kaye SB (2010) Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol 7(10):575\u2013582","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"9847_CR8","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900\u2013905","journal-title":"N Engl J Med"},{"issue":"2","key":"9847_CR9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2008.0013","volume":"6","author":"BH Segal","year":"2008","unstructured":"Segal BH, Freifeld AG, Baden LR, Brown AE, Casper C, Dubberke E, Gelfand M, Greene JN, Ison MG, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marcucci G, Montoya JG, Engemann AM, Rolston K, The AS (2008) Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 6(2):122\u2013174","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"9847_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","volume":"13","author":"AJ Windebank","year":"2008","unstructured":"Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27\u201346","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"9847_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.seminoncol.2005.11.011","volume":"33","author":"MJ de Jonge","year":"2006","unstructured":"de Jonge MJ, Verweij J (2006) Renal toxicities of chemotherapy. Semin Oncol 33(1):68\u201373","journal-title":"Semin Oncol"},{"issue":"10 Suppl 6","key":"9847_CR12","first-page":"9","volume":"18","author":"PJ Hesketh","year":"2004","unstructured":"Hesketh PJ (2004) Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology 18(10 Suppl 6):9\u201314","journal-title":"Oncology"},{"issue":"6","key":"9847_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","volume":"25","author":"S Roychowdhury","year":"2011","unstructured":"Roychowdhury S, Talpaz M (2011) Managing resistance in chronic myeloid leukemia. Blood Rev 25(6):279\u2013290","journal-title":"Blood Rev"},{"issue":"21","key":"9847_CR14","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-08-0581","volume":"14","author":"FL Chen","year":"2008","unstructured":"Chen FL, Xia W, Spector NL (2008) Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 14(21):6730\u20136734","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9847_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","volume":"7","author":"DL Wheeler","year":"2010","unstructured":"Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7(9):493\u2013507","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"9847_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s12094-011-0720-z","volume":"13","author":"GV Koukourakis","year":"2011","unstructured":"Koukourakis GV, Sotiropoulou-Lontou A (2011) Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol 13(10):710\u2013714","journal-title":"Clin Transl Oncol"},{"issue":"16","key":"9847_CR17","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2165\/11207720-000000000-00000","volume":"71","author":"KF Croom","year":"2011","unstructured":"Croom KF, Dhillon S (2011) Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 71(16):2213\u20132229","journal-title":"Drugs"},{"issue":"8","key":"9847_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nrclinonc.2011.45","volume":"8","author":"A Okines","year":"2011","unstructured":"Okines A, Cunningham D, Chau I (2011) Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8(8):492\u2013503","journal-title":"Nat Rev Clin Oncol"},{"issue":"11\u201312","key":"9847_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.drudis.2011.04.003","volume":"16","author":"S Choudhary","year":"2011","unstructured":"Choudhary S, Mathew M, Verma RS (2011) Therapeutic potential of anticancer immunotoxins. Drug Discov Today 16(11\u201312):495\u2013503","journal-title":"Drug Discov Today"},{"issue":"23","key":"9847_CR20","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1111\/j.1742-4658.2011.08182.x","volume":"278","author":"JE Weldon","year":"2011","unstructured":"Weldon JE, Pastan I (2011) A guide to taming a toxin\u2013recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278(23):4683\u20134700","journal-title":"FEBS J"},{"issue":"11","key":"9847_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1517\/14712590903348135","volume":"9","author":"G Manoukian","year":"2009","unstructured":"Manoukian G, Hagemeister F (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9(11):1445\u20131451","journal-title":"Expert Opin Biol Ther"},{"issue":"20","key":"9847_CR22","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","volume":"17","author":"PM LoRusso","year":"2011","unstructured":"LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17(20):6437\u20136447","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9847_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/CCO.0b013e32834b895c","volume":"23","author":"J Mathew","year":"2011","unstructured":"Mathew J, Perez EA (2011) Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 23(6):594\u2013600","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"9847_CR24","first-page":"1302","volume":"6","author":"RA Messmann","year":"2000","unstructured":"Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA (2000) A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 6(4):1302\u20131313","journal-title":"Clin Cancer Res"},{"key":"9847_CR25","doi-asserted-by":"crossref","unstructured":"Dean A, Talpaz M, Kantarjian H, Faderl S, Jabbour E, Kashani FR, O'Brien SM, Rosenblum M, Cortes JE (2010) Phase I clinical trial of the anti-CD33 immunotoxin HuM195\/rgel in patients with advanced myeloid malignancies. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 28, No 15_suppl (May 20 Supplement), 2010: 6549","DOI":"10.1200\/jco.2010.28.15_suppl.6549"},{"issue":"21","key":"9847_CR26","doi-asserted-by":"publisher","first-page":"17976","DOI":"10.1074\/jbc.M011085200","volume":"276","author":"S Liu","year":"2001","unstructured":"Liu S, Bugge TH, Leppla SH (2001) Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 276(21):17976\u201317984","journal-title":"J Biol Chem"},{"issue":"21","key":"9847_CR27","first-page":"6061","volume":"60","author":"S Liu","year":"2000","unstructured":"Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH (2000) Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 60(21):6061\u20136067","journal-title":"Cancer Res"},{"issue":"5","key":"9847_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/jnci\/djk065","volume":"99","author":"SA Williams","year":"2007","unstructured":"Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR (2007) A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99(5):376\u2013385","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"9847_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0966-842X(00)01722-4","volume":"8","author":"L Abrami","year":"2000","unstructured":"Abrami L, Fivaz M, van der Goot FG (2000) Adventures of a pore-forming toxin at the target cell surface. Trends Microbiol 8(4):168\u2013172","journal-title":"Trends Microbiol"},{"key":"9847_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","volume":"19","author":"RJ Collier","year":"2003","unstructured":"Collier RJ, Young JAT (2003) Anthrax toxin. Ann Rev Cell Dev Biol 19:45\u201370","journal-title":"Ann Rev Cell Dev Biol"},{"key":"9847_CR31","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jmb.2009.07.037","volume":"392","author":"AF Kintzer","year":"2009","unstructured":"Kintzer AF, Thoren KL, Sterling HJ, Dong KC, Feld GK, Tang II, Zhang TT, Williams ER, Berger JM, Krantz BA (2009) The protective antigen component of anthrax toxin forms functional octameric complexes. J Mol Biol 392:614\u2013629","journal-title":"J Mol Biol"},{"issue":"6","key":"9847_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.mam.2009.06.003","volume":"30","author":"RJ Collier","year":"2009","unstructured":"Collier RJ (2009) Membrane translocation by anthrax toxin. Mol Aspects Med 30(6):413\u2013422","journal-title":"Mol Aspects Med"},{"issue":"1\u20132","key":"9847_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0014-5793(99)01502-1","volume":"462","author":"R Pellizzari","year":"1999","unstructured":"Pellizzari R, Guidi-Rontani C, Vitale G, Mock M, Montecucco C (1999) Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS\/IFNgamma-induced release of NO and TNFalpha. FEBS Lett 462(1\u20132):199\u2013204","journal-title":"FEBS Lett"},{"key":"9847_CR34","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1006\/bbrc.1998.9040","volume":"248","author":"G Vitale","year":"1998","unstructured":"Vitale G, Pellizzari R, Recchi C, Napolitani G, Mock M, Montecucco C (1998) Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine\/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun 248:706\u2013711","journal-title":"Biochem Biophys Res Commun"},{"issue":"5364","key":"9847_CR35","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.280.5364.734","volume":"280","author":"NS Duesbery","year":"1998","unstructured":"Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF (1998) Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280(5364):734\u2013737","journal-title":"Science"},{"issue":"3","key":"9847_CR36","doi-asserted-by":"publisher","first-page":"e1002638","DOI":"10.1371\/journal.ppat.1002638","volume":"8","author":"JL Levinsohn","year":"2012","unstructured":"Levinsohn JL, Newman ZL, Hellmich KA, Fattah R, Getz MA, Liu S, Sastalla I, Leppla SH, Moayeri M (2012) Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog 8(3):e1002638","journal-title":"PLoS Pathog"},{"issue":"2","key":"9847_CR37","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1073\/pnas.0236849100","volume":"100","author":"S Liu","year":"2003","unstructured":"Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH (2003) Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 100(2):657\u2013662","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"9847_CR38","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1535-7163.MCT-06-0315","volume":"5","author":"RJ Abi-Habib","year":"2006","unstructured":"Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE (2006) A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol Cancer Ther 5(10):2556\u20132562","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"9847_CR39","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1074\/jbc.M707419200","volume":"283","author":"S Liu","year":"2008","unstructured":"Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH (2008) Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem 283(1):529\u2013540","journal-title":"J Biol Chem"},{"issue":"6","key":"9847_CR40","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/nbt1091","volume":"23","author":"S Liu","year":"2005","unstructured":"Liu S, Redeye V, Kuremsky JG, Kuhnen M, Molinolo A, Bugge TH, Leppla SH (2005) Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat Biotechnol 23(6):725\u2013730","journal-title":"Nat Biotechnol"},{"issue":"7","key":"9847_CR41","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-07-0148","volume":"6","author":"K Katayama","year":"2007","unstructured":"Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y (2007) Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6(7):2092\u20132102","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"9847_CR42","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"BR Davies","year":"2007","unstructured":"Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209\u20132219","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"9847_CR43","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","volume":"14","author":"NK Haass","year":"2008","unstructured":"Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS (2008) The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14(1):230\u2013239","journal-title":"Clin Cancer Res"},{"issue":"23","key":"9847_CR44","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1158\/1078-0432.CCR-07-1592","volume":"13","author":"R Hassan","year":"2007","unstructured":"Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J (2007) Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 13(23):7166\u20137171","journal-title":"Clin Cancer Res"},{"issue":"15","key":"9847_CR45","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-06-0346","volume":"12","author":"Y Zhang","year":"2006","unstructured":"Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, Le N, Ho M, Pastan I (2006) Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 12(15):4695\u20134701","journal-title":"Clin Cancer Res"},{"issue":"43","key":"9847_CR46","doi-asserted-by":"publisher","first-page":"17099","DOI":"10.1073\/pnas.0708101104","volume":"104","author":"Y Zhang","year":"2007","unstructured":"Zhang Y, Xiang L, Hassan R, Pastan I (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 104(43):17099\u201317104","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9847_CR47","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pep.2011.05.016","volume":"80","author":"AP Pomerantsev","year":"2011","unstructured":"Pomerantsev AP, Pomerantseva OM, Moayeri M, Fattah R, Tallant C, Leppla SH (2011) A Bacillus anthracis strain deleted for six proteases serves as an effective host for production of recombinant proteins. Protein Expr Purif 80(1):80\u201390","journal-title":"Protein Expr Purif"},{"issue":"5","key":"9847_CR48","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1158\/1535-7163.MCT-08-0024","volume":"7","author":"RW Alfano","year":"2008","unstructured":"Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Bromberg-White JL, Duesbery NS, Frankel AE (2008) Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther 7(5):1218\u20131226","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"9847_CR49","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/sj.onc.1207405","volume":"23","author":"VO Melnikova","year":"2004","unstructured":"Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN (2004) Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23(13):2347\u20132356","journal-title":"Oncogene"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-012-9847-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9847-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-012-9847-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:47Z","timestamp":1678560047000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-012-9847-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,28]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["9847"],"URL":"https:\/\/doi.org\/10.1007\/s10637-012-9847-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,28]]},"assertion":[{"value":"16 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}